This inventor holds 3 USPTO granted patents. Top assignees: Pharmacia Ab, Kabi Pharmacia Ab. Active years: 1994-1996.
Company Filing History:
Years Active: 1994-1996
Title: Thomas Berglindh: Innovator in Pharmaceutical Chemistry
Introduction
Thomas Berglindh is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for medical applications. With a total of 3 patents, his work focuses on innovative solutions for treating autoimmune diseases.
Latest Patents
Berglindh's latest patents include the invention of N-heterocyclic substituted salicylic acids. This compound is characterized by the formula Het--NR--SO.sub.2 --Ph.sup.2 --A--Ph.sup.1 (COOH)(OH) and its tautomeric forms, salts, solvates, C.sub.1-6 alkyl esters, and pharmaceutical compositions. The compound features benzene rings, with carboxy and hydroxy groups positioned ortho to one another. The heterocyclic ring includes conjugated double bonds and binds to nitrogen in NR. The invention emphasizes that A is a stable bridge against reduction, and R can be hydrogen or lower alkyl. This compound is particularly aimed at treating autoimmune diseases.
Career Highlights
Throughout his career, Thomas Berglindh has worked with prominent companies in the pharmaceutical industry, including Pharmacia AB and Kabi Pharmacia AB. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Berglindh has collaborated with notable colleagues such as Hubert Agback and Leif G. Ahrgren. These partnerships have likely enhanced his research and development efforts in the pharmaceutical field.
Conclusion
Thomas Berglindh stands out as an influential inventor in pharmaceutical chemistry, with a focus on innovative compounds for treating autoimmune diseases. His contributions through patents and collaborations reflect his commitment to advancing medical science.